Skip to main content

Advertisement

SpringerLink
Log in

Survivin and SIRT1: can be two prognostic factors in chronic myeloid leukemia?

  • Original Article
  • Published:
Comparative Clinical Pathology Aims and scope Submit manuscript

Abstract

Antiapoptotic molecules are important in the development, progression, and prognosis of malignant disorders. The aim of this study was to determine the expression of two distinct antiapoptotic molecules, SIRT1 and Survivin (SVV), in chronic myeloid leukemia (CML) and to compare them with hematological prognostic factors. In this study, we measured the expression of SVV and SIRT1 in 18 patients with typical Ph-positive chronic myeloid leukemia in chronic phases of the disease as well as in 18 matched healthy donors. SVV, SIRT1, and BCR/ABL expression were determined by quantitative-real-time polymerase chain reaction (Q-RT-PCR). HPRT was used as a reference gene to calculate SVV/HPRT and SIRT1/HPRT ratio, and ABL was used as an internal control for BCR/ABL expression. SVV was between 0.00 and 2.39-fold (median 0.204) and SIRT1 was between 0.00 and 33.32-fold (median 0.186). In our study, both SVV and SIRT1 were lower in patients than in the controls (p = 0.001 and 0.001, respectively). Although the expression of SVV and SIRT1 was decreased in patients with chronic phase (0.043 and 0.043-fold, respectively), a potent expression upregulation of both genes was found in K562, Jurkat, and U937 cell lines. Despite lower expression of both SVV and SIRT1 at chronic phase, a significant correlation was found between SVV expression levels and minor Hb concentration (<10) (p = 0.005). In addition, there was important correlation between BCR/ABL copy number and older age (≥60) and PLT count (p = 0.027 and p = 0.001, respectively). Of course, no specific clinicohematological or prognostic profile was associated with SIRT1 expression. In contrast with SIRT1 expression, high SVV expression and high BCR/ABL copy number could be introduced as prognostic factors in chronic phase of CML, but this finding must be evaluated in other phase of CML and with a higher number of subjects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Adida C, Recher C, Raffoux E, Daniel MT, Taksin AL, Rousselot P et al (2000a) Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 111(1):196–203

    Article  CAS  PubMed  Google Scholar 

  • Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J et al (2000b) Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96(5):1921–1925

    CAS  PubMed  Google Scholar 

  • Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3(8):917–921

    Article  CAS  PubMed  Google Scholar 

  • Badran A, Yoshida A, Wano Y, Imamura S, Kawai Y, Tsutani H et al (2002) Expression of the antiapoptotic gene survivin in chronic myeloid leukemia. Anticancer Res 23(1B):589–592

    Google Scholar 

  • Badran A, Yoshida A, Wano Y, Mutoh M, Imamura S, Yamashita T et al (2003) Expression of the anti-apoptotic gene survivin in myelodysplastic syndrome. Int J Oncol 22(1):59–64

    CAS  PubMed  Google Scholar 

  • Bradbury C, Khanim F, Hayden R, Bunce C, White D, Drayson M et al (2005) Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19(10):1751–1759

    Article  CAS  PubMed  Google Scholar 

  • Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y et al (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303(5666):2011–2015

    Article  CAS  PubMed  Google Scholar 

  • Carter BZ, Milella M, Altieri DC, Andreeff M (2001) Cytokine-regulated expression of survivinin myeloid leukemia. Blood 97(9):2784–2790

    Article  CAS  PubMed  Google Scholar 

  • Cheung CHA, Huang C-C, Tsai F-Y, Lee JY-C, Cheng SM, Chang Y-C et al (2013) Survivin–biology and potential as a therapeutic target in oncology. OncoTargets Ther 6:1453

    Article  CAS  Google Scholar 

  • Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B et al (2004) Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305(5682):390–392

    Article  CAS  PubMed  Google Scholar 

  • Conte E, Stagno F, Guglielmo P, Scuto A, Consoli C, Messina A (2005) Survivin expression in chronic myeloid leukemia. Cancer Lett 225(1):105–110

    Article  CAS  PubMed  Google Scholar 

  • Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M et al (2001) Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97(9):2777–2783

    Article  CAS  PubMed  Google Scholar 

  • Hernández-Boluda J-C, Bellosillo B, Vela M-C, Colomer D, Alvarez-Larrán A, Cervantes F (2005) Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. Leuk Lymphoma 46(5):717–722

    Article  PubMed  Google Scholar 

  • Huang J, Lyu H, Wang J, Liu B (2015) Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia. Cancer Lett 366(2):160–172

    Article  CAS  PubMed  Google Scholar 

  • Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee N-R et al (2008) SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 32(10):1523–1531

    Article  PubMed  Google Scholar 

  • Jang S-H, Min K-W, Paik SS, Jang K-S (2012) Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma. J Clin Pathol 65(8):735–739

    Article  PubMed  Google Scholar 

  • Jung W, Hong KD, Jung WY, Lee E, Shin BK, Kim HK et al (2013) SIRT1 expression is associated with good prognosis in colorectal cancer. Korean J Pathol 47(4):332–339

    Article  PubMed  PubMed Central  Google Scholar 

  • Kamihira S, Yamada Y, Hirakata Y, Tomonaga M, Sugahara K, Hayashi T et al (2001) Aberrant expression of caspase cascade regulatory genes in adult T‐cell leukaemia: survivin is an important determinant for prognosis. Br J Haematol 114(1):63–69

    Article  CAS  PubMed  Google Scholar 

  • Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB (1990) Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 88(1):1–8

    Article  CAS  PubMed  Google Scholar 

  • Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T et al (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21(2):266–281

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Luo J, Nikolaev AY, Imai S-I, Chen D, Su F, Shiloh A et al (2001) Negative control of p53 by Sir2α promotes cell survival under stress. Cell 107(2):137–148

    Article  CAS  PubMed  Google Scholar 

  • Martinez A, Bellosillo B, Bosch F, Ferrer A, Marcé S, Villamor N et al (2004) Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 164(2):501–510

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7(6):441–453

    Article  CAS  PubMed  Google Scholar 

  • Mobahat M, Narendran A, Riabowol K (2014) Survivin as a preferential target for cancer therapy. Int J Mol Sci 15(2):2494–2516

    Article  PubMed  PubMed Central  Google Scholar 

  • Mori N, Yamada Y, Hata T, Ikeda S, Yamasaki Y, Tomonaga M et al (2001) Expression of survivin in HTLV-I-infected T-cell lines and primary ATL cells. Biochem Biophys Res Commun 282(5):1110–1113

    Article  CAS  PubMed  Google Scholar 

  • Mori A, Wada H, Nishimura Y, Okamoto T, Takemoto Y, Kakishita E (2002) Expression of the antiapoptosis gene survivin in human leukemia. Int J Hematol 75(2):161–165

    Article  CAS  PubMed  Google Scholar 

  • Nakamura S, Takemura T, Tan L, Nagata Y, Yokota D, Hirano I et al (2011) Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells. Carcinogenesis 32(12):1758–1772

    Article  CAS  PubMed  Google Scholar 

  • Nakayama K, Kamihira S (2002) Survivin an important determinant for prognosis in adult T-cell leukemia: a novel biomarker in practical hemato-oncology. Leuk Lymphoma 43(12):2249–2255

    Article  CAS  PubMed  Google Scholar 

  • O’Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S et al (2002) The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100(5):1628–1633

    Article  PubMed  Google Scholar 

  • Rahimian A, Soleimani M, Kaviani S, Aghaee-Bakhtiari S, Atashi A, Arefian E et al (2011) Bypassing the maturation arrest in myeloid cell line U937 by over-expression of microRNA-424. Hematology 16(5):298–302

    Article  CAS  PubMed  Google Scholar 

  • Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ (2004) Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 22(9):1682–1688

    Article  CAS  PubMed  Google Scholar 

  • Thielen N, Ossenkoppele G, Schuurhuis G, Janssen J (2011) new insights into the pathogenesis of chronic myeloid leukaemia: towards a path to cure. Neth J Med 69(10):430–440

  • Vaziri H, Dessain SK, Eaton EN, Imai S-I, Frye RA, Pandita TK et al (2001) hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase. Cell 107(2):149–159

    Article  CAS  PubMed  Google Scholar 

  • Yuan H, Wang Z, Li L, Zhang H, Modi H, Horne D et al (2012) Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 119(8):1904–1914

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Health Research Institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

    Fatemeh Salari, Ahmad Ahmadzadeh, Mohammad Ali Jalali far & Najmaldin Saki

  2. Department of Medical Genetics, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

    Javad Mohammdai-asl

  3. Department of Biostatistics and Epidemiology, School of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

    Amal Saki Malehi

  4. Department of Laboratory Science, School of Paramedicine, Ahvaz Jundishapur of Medical Sciences, Ahvaz, Iran

    Zari Tahannejad Asadi

Authors
  1. Fatemeh Salari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Javad Mohammdai-asl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amal Saki Malehi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ahmad Ahmadzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohammad Ali Jalali far
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zari Tahannejad Asadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Najmaldin Saki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Najmaldin Saki.

Ethics declarations

This study was approved by the local ethics committee of Ahvaz Jundishapur University of Medical Sciences and with the 1964 Helsinki Declaration. Written informed consent was obtained from all patients and normal individuals.

Conflict of interest

The authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salari, F., Mohammdai-asl, J., Malehi, A.S. et al. Survivin and SIRT1: can be two prognostic factors in chronic myeloid leukemia?. Comp Clin Pathol 25, 415–420 (2016). https://doi.org/10.1007/s00580-015-2201-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00580-015-2201-1

Keywords

Search

Navigation